E N I G M A MARKETING RESEARCH

Similar documents
Pharmaceutical Sector Inquiry Presentation of the Preliminary Report. 28 November 2008

PATENTS FOR CHEMICALS, PHARMACEUTICALS AND BIOTECHNOLOGY

Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry

Implementation of Regulation (EC) No 1107/ State of affairs -

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

Mathys & Squire. Agri-Tech Intellectual Property Rights in Europe. mathys-squire.com

ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU.

DRAFTING THE APPLICATION FOR THE GRANT OF A PATENT OR UMC ΟΡΓΑΝΙΣΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗΣ ΙΔΙΟΚΤΗΣΙΑΣ

IS LIMITED REGISTRATION OF IRON OXIDE PELLETS UNDER REACH AN OPTION?

Addition of D4, D5 and D6 to SVHC candidate list

ACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY

WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION OF INVENTIONS AND RESEARCH RESULTS

Carnegie Endowment for International Peace

Fact Sheet IP specificities in research for the benefit of SMEs

IP, STRATEGY, PROCEDURE, FTO Peter ten Haaft (PhD, Dutch and European Patent Attorney)

Hong Kong. Patent Application. Hong Kong Trademark & Design Protection Agency Ltd. HKT&DPA Ltd All Rights Reserved.

Ten Myths: Intellectual Property Rights and the Montreal Protocol

Welcome to the Tuesday 17th June 2014

Quality Systems, Accreditation and the Food Sector

Observations from Pharma

Crop Protection European Regulatory Conference

APIs global business developments

Intellectual Property

CHEMISTRY AND PHARMACEUTICALS PATENT ATTORNEYS TRADE MARK ATTORNEYS

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries

Key issues in building a strong life sciences patent portfolio. Tom Harding and Jane Wainwright Potter Clarkson LLP

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Why intellectual property can be a barrier to TT

WIPO NATIONAL WORKSHOP FOR PATENT LAWYERS

TRIPS Post Grant Flexibilities: Key Exceptions to Patent Holders' Rights. David Vivas Eugui

Regulation on medicinal products for paediatric use

Ai Group Submission. in response to the REVIEW OF ELECTRICITY (CONSUMER SAFETY) ACT 2004 ISSUES PAPER

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

Flexibilities in the Patent System

Analytical Test Report 05

Monitoring R&D resource flows: Global resources and challenges

Enforcement Regulations of the Pharmaceutical Affairs Law

The TRIPS Agreement and Patentability Criteria

Research Collection. Comment on Henkel, J. and F. Jell "Alternative motives to file for patents: profiting from pendency and publication.

Use of Patent Landscape Reports for Commercial Activities

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:

OMCL Network of the Council of Europe GENERAL DOCUMENT

Key Features of Patent and Utility Models Protection

Creating a Global Culture of Stewardship Chris Holdgreve, ETS Executive Director

Submission to the Department of Industry, Innovation and Science on the Productivity Commission s Final Report on Intellectual Property Arrangements

Leveraging Intellectual Property for Success

Intellectual Property Initiatives

"Workshops on key economic issues regarding the. enforcement of IPR in the European Union"

The Face of the Patent is not the Whole Story : Determining Effective Patent Life in the US. Anne Marie Clark, Ph.D. and Heidi Berven,, Ph.D., J.D.

QANTM Intellectual Property Limited (ASX: QIP)

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

California State University, Northridge Policy Statement on Inventions and Patents

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Office for Nuclear Regulation

(3) How does one obtain patent protection?

LAW ON TECHNOLOGY TRANSFER 1998

Paul Sanderson CEO. Our philosophy. HGF Limited

Case Study HYDRO-COAT: Duly protecting research project results


Recast de la législation européenne et impact sur l organisation hospitalière

Patent Landscape Report on Recycling Technologies for Endof Life ICT Equipment

Study of Comparative Advantages of Chinese and Indian Pharmaceutical Industries under Globalization

COUNCIL OF THE EUROPEAN UNION. Brussels, 9 December 2008 (16.12) (OR. fr) 16767/08 RECH 410 COMPET 550

Topic 2: The Critical Role of IP Policies in Modern Economies

Re: The Cabinet s Consultation, Open Standards: Open Opportunities, Flexibility, and Efficiency in Government IT

Change the Game, SMEs! Leverage on your IP

Nitya Nanda. The Energy and Resources Institute (TERI)

Patenting trends in Indian pharmaceutical industry

Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents

Science, Technology & Innovation Indicators

Healthcare and Life Sciences

TRIPS and Access to Medicines. WR Briefing

(copy of one submitted by letter of. Division Research Grants, the National Institutes of Health).

Overview of Intellectual Property Policy and Law of China in 2017

TABLE OF CONTENTS DUPONT TYVEK MEDICAL PACKAGING TRANSITION PROJECT (MPTP) EXECUTIVE SUMMARY JUNE 2016 THE FINAL PHASE EXECUTIVE SUMMARY 2

Derwent Innovation Legal Status: Predictive Data on Derwent Innovation

QUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile

Artificial Intelligence (AI) and Patents in the European Union

Mini MBA: Oil & Gas and Energy Management

CBD/ Access and Benefit Sharing

Master Kush. Results at a Glance. Green Leaf Lab proudly follows TNI 2009 Quality Standards

Key Strategies for Your IP Portfolio

University joins Industry: IP Department. Georgina Marjanet Ferrer International, SA

API hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy.

IP Strategies to Enhance Competitiveness: India s Experience

Overview of the BPR and Authorisation procedures

THE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN

MORGAN STATE UNIVERSITY PROCEDURES ON PATENTS AND TECHNOLOGY TRANSFER APPROVED BY THE PRESIDENT NOVEMBER 2, 2015

Contents. About Grupo Plimon Global Presence Worldwide Locations Business Units Production Site / R&D Quality Guarantee Fair Trade & CSR

Procedure for introducing current scientific and technical knowledge into the authorisation procedure for plant protection products

National Intellectual Property Office in Sri Lanka (NIPO)

Official Cannalysis Report License#: C70

SCIENCE + BEAUTY. Technical Expertise for the Beauty Industry. 6 pages total

Antitrust & Competition

peace of mind For from development to commercial supply

Presented at GIZ/SAWTEE Training on IPR 1-2 March 2012, Laltipur. Ratnakar Adhikari South Asia Watch on Trade, Economics and Environment

M A R K E T L E D P R O P O SA LS

Finland Russia Ukraine CONTENTS

Transcription:

E N I G M A MARKETING RESEARCH New Generic Agrochemicals - post 2009 A new report, the 7th in the series on the generic agrochemical market which will assist: Generic Manufacturers Marketing Companies R&D-based Multinationals Contract Manufacturers Intermediate Suppliers Investment Companies Identify their next generic active substance for development. Recognise new opportunities in the buoyant and expanding generic agrochemical sector. Understand the issues of developing new generic agrochemicals. Navigate registration procedures in all the major markets.

New Generic Agrochemicals post 2009 Features 41 active substances whose patents will expire between 2009-2013 (in some countries patent term extension beyond 2013 may exist) or granted patent term extension will expire between 2011-2015. acetamiprid acibenzolar-s-methyl amicarbazone azoxystrobin bifenazate cafenstrole carfentrazone-ethyl cinidon-ethyl clothianidin cyazofamid cyclosulfamuron cyprodinil emamectin benzoate ethoxysulfuron famoxadone fenamidone fenhexamid florasulam flufenacet flupyrsulfuron-methyl-sodium indanofan indoxacarb iprovalicarb isoxaflutole kresoxim-methyl mefenpyr-diethyl mesotrione picolinafen picoxystrobin propoxycarbazone pyraflufen-ethyl quinoxyfen silthiofam spinosad spiroxamine sulfentrazone thiacloprid trifloxystrobin triticonazole tritosulfuron zoxamide Active Substances profiled in this report by inventor company. FMC (2) Others (6) Syngenta (6) Nihon Nohyaku (2) Du Pont (3) Dow AgroSciences (4) BASF (6) Bayer CropScience (12)

Patents Key data in active substance profile: European patent number and expiry date UK Supplementary Protection Certificates (SPCs) US patent number and expiry date INPADOC patent family Product Profile Activity Combination active substances Trade names Biochemistry Mode of action Uses Types of formulated products Major crops Major markets Registration issues US Environmental Protection Agency (EPA) EU Directive 91/414 Web links to registration documents Chemistry Minimum purity of technical material Generic manufacturing companies Synthetic pathway Alternative synthetic pathway (where appropriate) Key intermediates Summary Analysis of the opportunity for generic competition.

Report Outline 1: Introduction to the global agrochemical market In 2007, the agrochemical industry grew substantially by nearly 10% and there is significant optimism that a period of sustained growth over the next five years will occur. This section looks at some of the reasons for this optimism. 2: Defending a market post patent expiry With over 70% of all products off-patent the top six R&D based companies control over 75% of the market how do they achieve this? How do inventor companies defend markets once patents have expired? In preparation for patent expiry a variety of strategic options are utilised by the inventor company to defend market share: Intellectual Property Rights Protected Registration Data Technical Defence via Process Know How Marketing Alliances - Authorised Generic 3: Developing a new generic agrochemical With many active substances coming off patent choosing the right generic to develop requires analysis of the following key areas: The Marketing Environment Intellectual Property Rights Chemistry/Technology of Manufacture Registration Issues Each area is reviewed and the key strategies employed by generic companies to enter markets are discussed. 4: Profiles of 41 active substances The Active Substance profiles contained in this report will help you determine which strategy, or combination of strategies is likely to be employed by the patent holder in order to protect market share. 5: Registration Procedures in the Major Agrochemical Markets: EU, USA, Japan, Brazil, Australia, China and India

TABLE OF CONTENTS 1 Introduction to the global agrochemical market Title 1.1 Major drives for agrochemicals in the crop sector 1.2 Rising manufacturing costs of agrochemicals 1.3 Products 20 1.3.1 Proprietary products 21 1.3.2 Proprietary off-patent products 21 1.3.3 Generic products 21 1.4 Companies 22 1.4.1 R&D-based companies 22 1.4.2 Generic companies 23 16 18 3 Developing a new generic agrochemical 3.3 Regional variations in the demand for generic agrochemicals 3.4 Potential new generic agrochemicals 53 3.4.1 Candidate active substances 53 3.5 Choosing the right generic 55 3.5.1 The marketing environment 55 3.5.2 The manufacturing process for active substances 3.5.3 Intellectual Property Rights (IPR) 56 3.5.4 Registration and data protection issues 57 3.6 Generic market entry strategies 63 3.6.1 Mergers and acquisitions 63 3.6.2 Product acquisitions 63 3.6.3 Marketing alliances authorised generics 63 3.6.4 Contract manufacture 64 3.6.5 Task forces 64 52 55 2 Defending a market post patent expiry 4 Profiles of Active Substances Title 2.1 Data protection 26 2.2 Data protection and market exclusivity 27 2.2.1 Existing Active Substances (EAS) 27 2.2.2 New Active Substances (NAS) 34 2.3 Intellectual Property Rights (IPR) 41 2.3.1 Supplementary Protection Certificates (SPCs) 2.3.2 Patent portfolios 43 2.4 Other post-patent strategies 44 2.4.1 Technical defence via process know-how 44 2.4.2 Key intermediates 44 41 Active Substance Active Substance Introduction 65 1 acetamiprid 66 2 acibenzolar-s-methyl 75 3 amicarbazone 82 4 azoxystrobin 88 5 bifenazate 97 6 cafenstrole 104 7 carfentrazone-ethyl 109 8 cinidon-ethyl 118 3 Developing a new generic agrochemical Title 3.1 Generic companies 47 3.1.1 Mixed portfolio of generic and proprietary off-patent products 3.1.2 Marketing companies 49 3.1.3 AS manufacturing companies 49 3.2 Increasing percentage of off-patent products 50 47 9 clothianidin 124 10 cyazofamid 131 11 cyclosulfamuron 140 12 cyprodinil 146 13 emamectin benzoate 152 14 ethoxysulfuron 157 15 famoxadone 164 16 fenamidone 172 17 fenhexamid 179 18 florasulam 186

4 Profiles of Active Substances Active Substance Active Substance 19 flufenacet 194 20 flupyrsulfuron-methyl-sodium 200 21 indanofan 207 22 indoxacarb 212 23 iprovalicarb 220 24 isoxaflutole 227 25 kresoxim-methyl 235 26 mefenpyr-diethyl 242 27 mesotrione 248 28 picolinafen 255 29 picoxystrobin 261 30 propoxycarbazone 268 31 pyraflufen-ethyl 276 32 quinoxyfen 282 33 silthiofam 291 34 spinosad 295 35 spiroxamine 302 36 sulfentrazone 308 37 thiacloprid 314 38 trifloxystrobin 322 39 triticonazole 330 40 tritosulfuron 337 41 zoxamide 343 5: Registration Procedures in the Major Agrochemical Markets Title 5.1.2.2 Data for existing ASs 355 5.1.2.3 Data to maintain or amend the Annex I inclusion 5.1.3 Registration requirements for generic pesticides 355 355 5.1.3.1 Pre-Annex I inclusion 355 5.1.3.2 Post-Annex I inclusion 356 5.1.3.3 Regulatory strategy 356 5.1.3.4 Protected data 357 5.1.3.5 Re-registration requirements 357 5.1.3.6 Vertebrate data 358 5.1.4 The future 358 5.1.5 Summary 360 5.2 The United States 362 5.2.1 Registration procedures 362 5.2.1.1 The Environmental Protection Agency 362 5.2.1.2 State registrations 362 5.2.1.3 Pesticide Registration Improvement Act of 2003 (PRIA) 363 5.2.1.4 Data submission 363 5.2.1.5 Review of existing pesticides 364 5.2.1.6 Re-registration procedure 364 5.2.1.7 Registration data requirements 366 5: Registration Procedures in the Major Agrochemical Markets Title 5.1 The European Union 351 5.1.1 Registration procedures 351 5.1.1.1 Introduction of 91/414/EEC 351 5.1.1.2 Data submissions 351 5.2.2 Data protection 366 5.2.3 Registration requirements for generic pesticides 366 5.2.3.1 Data compensation 367 5.2.4 The future 368 5.2.5 Summary 370 5.3 Japan 372 5.3.1 Registration procedures 372 5.1.1.3 Criteria for evaluating ASs and plant protection products 352 5.3.1.1 The Agricultural Chemicals Inspection Station (ACIS) 372 5.1.1.4 Review of existing ASs 352 5.1.1.5 Registration of new ASs 354 5.1.2 Data protection 355 5.1.2.1 Data for new ASs 355 5.3.1.2 Data Submission 372 5.3.1.3 Good laboratory practice 373 5.3.1.4 International harmonisation 373 5.3.2 Data protection 374

5: Registration Procedures in the Major Agrochemical Markets 5: Registration Procedures in the Major Agrochemical Markets Title Title 5.3.3 Data requirements for generic products 374 5.3.4 Summary 375 5.4 Brazil 376 5.4.1 Registration procedures 376 5.4.2 Data protection 376 5.4.3 Registration requirements for generic pesticides 377 5.4.4 The future 377 5.4.5 Summary 379 5.5 Australia 380 5.5.1 Registration procedures 380 5.5.1.1 The Australian Pesticides and Veterinary Medicines Authority 380 5.5.1.2 Data submission 381 5.5.3 Data protection 382 5.5.4 Data requirements for generic products 382 5.5.4.1 Category 7 382 5.5.4.2 Category 6 383 5.5.4.3 Category 5 383 5.5.4.4 Category 10 383 5.5.4.5 Category 24 383 5.5.5 Summary 384 5.6 China 385 5.6.1 Registration procedures 385 5.6.1.1 Field trial registration 385 5.6.1.2 Temporary pesticide registration 385 5.6.1.3 Formal pesticide registration 385 5.6.1.4 Data submission 386 5.6.2 Data protection 387 5.6.3 Data requirements for generic pesticides 387 5.6.4 The future 387 5.6.5 Summary 388 5.7 India 389 5.7.1 Registration procedures 389 5.7.2 Data protection 389 5.7.3 Generic registration requirements 389 5.7.4 The future 390 5.7.5 Summary 391

Purchase Contract The purchase price for this study is 3,250 Company Name: Address for delivery: Fax: Phone: E-mail: Authorising Agent (print): (signature): Position in Company: Date: Please print out and fax or E-mail to: Fax: 44 + (0) 1477-533346 E-mail: emrgoostrey@msn.com www.enigmamarketingresearch.com

DISCLAIMER Whilst every effort has been made to ensure that the patent information given herein is accurate, this report cannot be considered to be an exhaustive review of the patents status of the compound and no guarantee can be given as to its accuracy or completeness. This report identifies those patents believed to be the basic product patents for the compound in question. However, it is possible that there may be other patents and patent applications, not identified in this report, relating to inter alia particular derivatives, salts, isomers, crystalline forms, uses, compositions and processes for the manufacture of the product, and which may be relevant to the commercialisation of the product. Unless otherwise stated, the patent expiry dates given are projected expiry dates based on the filing dates (or where appropriate grant dates) of the patents, assuming that all of the annual renewal fees have been paid and assuming also that the patents have not been revoked or otherwise allowed to lapse. Moreover, in certain countries it is possible for the term of a patent relating to an agrochemical to be extended and, where we are aware of such extensions, they have been noted in this report. However, the absence of any mention of patent term extensions in this report should not be taken as an authoritative statement that no such extensions have been granted. We would strongly recommend that the official UK (or other country) patent office register be inspected to obtain final confirmation as to the current status or expiry dates of the patents. The fact that any product is identified as being manufactured or offered for sale is not an indication to import, sell, keep or use such products in any particular country as there may be patents in force which may make such acts unlawful. Any person considering doing so should make all necessary enquiries to ensure that to import, sell, keep or use such products should not infringe any persons patent rights in those countries which he/she intends to do so.